Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis.
Clinical remission
Mucosal healing
Ulcerative colitis
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
14
11
2019
accepted:
09
12
2019
entrez:
4
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
ppublish
Résumé
The use of monotherapy with intensive granulocyte and monocyte adsorptive apheresis (GMA) or a Janus kinase (JAK) inhibitor has been limited to patients with refractory ulcerative colitis (UC). The efficacy and safety of combination therapy with tofacitinib (TOF) plus intensive GMA (two sessions per week) for refractory UC have not been evaluated. This retrospective study evaluated the 10-week efficacy of combination therapy with TOF plus intensive GMA in patients with refractory UC. Of seven patients who received a combination therapy with TOF plus intensive GMA, 71.4% achieved clinical remission at 10 weeks. The percentages of patients with mucosal healing and complete mucosal healing at 10 weeks were 100% and 42.9%, respectively. The mean full Mayo score and endoscopic subscore at baseline were 8.71 ± 0.80 and 2.4 ± 0.2, respectively, and the corresponding values at 10 weeks were 1.57 ± 0.48 and 0.6 ± 0.2 (P < 0.01), respectively. Adverse events of an orolabial herpes and temporary increase in creatinine phosphokinase (CK) and triglyceride were observed in three patients. Based on these outcomes, combination therapy with TOF plus intensive GMA was well tolerated and may be useful for induction of clinical remission in patients with refractory UC.
Sections du résumé
BACKGROUND
BACKGROUND
The use of monotherapy with intensive granulocyte and monocyte adsorptive apheresis (GMA) or a Janus kinase (JAK) inhibitor has been limited to patients with refractory ulcerative colitis (UC). The efficacy and safety of combination therapy with tofacitinib (TOF) plus intensive GMA (two sessions per week) for refractory UC have not been evaluated.
METHODS
METHODS
This retrospective study evaluated the 10-week efficacy of combination therapy with TOF plus intensive GMA in patients with refractory UC.
RESULTS
RESULTS
Of seven patients who received a combination therapy with TOF plus intensive GMA, 71.4% achieved clinical remission at 10 weeks. The percentages of patients with mucosal healing and complete mucosal healing at 10 weeks were 100% and 42.9%, respectively. The mean full Mayo score and endoscopic subscore at baseline were 8.71 ± 0.80 and 2.4 ± 0.2, respectively, and the corresponding values at 10 weeks were 1.57 ± 0.48 and 0.6 ± 0.2 (P < 0.01), respectively. Adverse events of an orolabial herpes and temporary increase in creatinine phosphokinase (CK) and triglyceride were observed in three patients.
CONCLUSIONS
CONCLUSIONS
Based on these outcomes, combination therapy with TOF plus intensive GMA was well tolerated and may be useful for induction of clinical remission in patients with refractory UC.
Identifiants
pubmed: 32010420
doi: 10.14740/jocmr4037
pmc: PMC6968921
doi:
Types de publication
Journal Article
Langues
eng
Pagination
36-40Informations de copyright
Copyright 2020, Tanida et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Gastroenterology. 2012 Feb;142(2):257-65.e1-3
pubmed: 22062358
Inflamm Bowel Dis. 2013 Jul;19(8):1700-9
pubmed: 23665965
J Biol Chem. 2003 May 9;278(19):16777-81
pubmed: 12615922
N Engl J Med. 2013 Aug 22;369(8):699-710
pubmed: 23964932
N Engl J Med. 2017 May 4;376(18):1723-1736
pubmed: 28467869
Digestion. 2004;70(1):36-44
pubmed: 15297776
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
Am J Gastroenterol. 2009 Dec;104(12):2990-5
pubmed: 19724269
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
N Engl J Med. 2012 Aug 16;367(7):616-24
pubmed: 22894574
Ther Apher. 1998 May;2(2):134-41
pubmed: 10225715
Ther Apher Dial. 2018 Jun;22(3):295-300
pubmed: 29790276
Dig Dis Sci. 2002 Jun;47(6):1334-41
pubmed: 12064810
J Clin Med Res. 2015 Nov;7(11):884-9
pubmed: 26491502
Lancet. 2012 Nov 3;380(9853):1606-19
pubmed: 22914296
Aliment Pharmacol Ther. 2010 Dec;32(11-12):1297-306
pubmed: 21050231
Ther Apher Dial. 2003 Feb;7(1):48-59
pubmed: 12921115
Gut. 2002 Sep;51(3):379-85
pubmed: 12171960
Scand J Gastroenterol. 2007 Feb;42(2):221-7
pubmed: 17327942